Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease pre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Infect Dis
Hauptverfasser: Grinspoon, Steven K, Douglas, Pamela S, Hoffmann, Udo, Ribaudo, Heather J
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2020
Schlagworte:
Supplement Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7347079/
https://ncbi.nlm.nih.gov/pubmed/32645161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiaa098
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge